HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, July 19, 2018 (HealthDay News) -- After the U.S. Food and Drug Administration announced last week that certain brands of blood pressure medicines contained a carcinogen and were being recalled, many patients may wonder what's next for their cardiovascular care.
The FDA said it mandated the recall because valsartan medicines from a Chinese manufacturer, Zhejiang Huahai Pharmaceuticals, were found to contain N-nitrosodimethylamine (NDMA), "a probable human carcinogen."
The agency noted that not all valsartan medicines for high blood pressure or heart failure are being recalled, only the affected brands.
"To determine whether a specific product has been recalled, patients should look at the drug name and company name on the label of their prescription bottle. If the information is not on the bottle, patients should contact the pharmacy that dispensed the medicine," the FDA said in an agency news release.
The recalled products include valsartan distributed by: Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd. It also includes valsartan/hydrochlorothiazide formulations distributed by Solco Healthcare and Teva.
But even if you are taking one of the recalled meds, don't stop using it immediately. The FDA stressed that "because valsartan is used in medicines to treat serious medical conditions, patients taking the recalled valsartan-containing medicines should continue taking their medicine until they have a replacement product."
One cardiologist agreed with that advice.
"The best remedy we are telling our patients is to contact their pharmacist and request they take an appropriate brand that does not have this impurity," said Dr. Satjit Bhusri, a heart specialist at Lenox Hill Hospital in New York City.
"There are many other substitutes for this medication, and that is an important discussion all patients should have with their physician," Bhusri said.
He pointed out that "patients on the heart failure combo drug Entresto, which contains valsartan, have not been affected."
Dr. Michael Goyfman directs clinical cardiology at Northwell Health's Long Island Jewish Forest Hills in New York City. He stressed that none of this should undermine people's faith in valsartan.
"The contaminant itself is the issue; valsartan otherwise remains an effective medication to treat high blood pressure and heart failure," Goyfman said.
And he agreed that no one should stop taking the recalled drugs immediately.
"Doing so may worsen their blood pressure and can lead to worsening heart failure, a stroke or a heart attack, which are possibly more significant risks than those from NDMA exposure," Goyfman said.
The FDA added, "Zhejiang Huahai has stopped distributing its valsartan API [active pharmaceutical ingredient], and the FDA is working with the affected companies to reduce or eliminate the impurity from future products."
Find out more about the care of high blood pressure at the American Heart Association.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.